Magseed application for detecting recurrent lymph node metastasis in papillary thyroid cancer: A novel minimally invasive Approach.

Magseed Metastasis Minimally invasive surgery Papillary thyroid cancer

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
28 Aug 2024
Historique:
received: 10 06 2024
revised: 12 08 2024
accepted: 23 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

Papillary thyroid cancer is associated with lymph node metastasis and tumor recurrence that need repeated surgery, entailing surgical challenges with a high risk of complications such as nerve damage and bleeding. Magseed is a metal coil used to detect non-palpable lesions and is an established modality in breast cancer surgery. In this case series, we explore the feasibility of Magseed in metastasis surgery of papillary thyroid cancer. Under the guidance of ultrasonography, Magseed is injected into the target tissue and intraoperatively detected with a handheld magnetometer probe, Sentimag®. Five patients with recurrence of papillary thyroid cancer were operated on with focused Magseed-guided localization. All patients had repeated surgery and radioiodine treatments. Four of the patients had lymph node metastasis hidden in the fibrosis, and one patient had recurrent tumor tissue on the left side of the larynx. Magseed was easy to use, safe, and precise in detecting the target tissue.

Identifiants

pubmed: 39208690
pii: S0748-7983(24)00676-0
doi: 10.1016/j.ejso.2024.108624
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108624

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors do not have any financial and personal relationships with other people or organizations that could inappropriately influence (bias) this work.

Auteurs

Ivan Shabo (I)

Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, SE 171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 171 77, Stockholm, Sweden. Electronic address: ivan.shabo@ki.se.

Athanasios Zouzos (A)

Department of Oncology-Pathology, Karolinska Institutet, SE 171 77, Stockholm, Sweden; Department of Radiology, Karolinska University Hospital, SE 171 76, Stockholm, Sweden.

Hanna Fredholm (H)

Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, SE 171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 171 77, Stockholm, Sweden.

Robert Bränström (R)

Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, SE 171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 171 77, Stockholm, Sweden.

Anders Höög (A)

Department of Oncology-Pathology, Karolinska Institutet, SE 171 77, Stockholm, Sweden; Department of Pathology, Karolinska University Hospital, SE 171 76, Stockholm, Sweden.

Magnus Kjellman (M)

Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, SE 171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 171 77, Stockholm, Sweden.

Catharina Ihre-Lundgren (C)

Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, SE 171 76, Stockholm, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, SE 171 77, Stockholm, Sweden.

Classifications MeSH